Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP869707.RAPdhNVmmhjPnmmWMSenyOoUpkUfrCL_RChO-gnIlKwSM130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP869707.RAPdhNVmmhjPnmmWMSenyOoUpkUfrCL_RChO-gnIlKwSM130_assertion type Assertion NP869707.RAPdhNVmmhjPnmmWMSenyOoUpkUfrCL_RChO-gnIlKwSM130_head.
- NP869707.RAPdhNVmmhjPnmmWMSenyOoUpkUfrCL_RChO-gnIlKwSM130_assertion description "[The Maraviroc versus Optimized Therapy in Viremic Antiretroviral Treatment-Experienced Patients (MOTIVATE) studies compared maraviroc versus placebo in treatment-experienced patients with CCR5-using (R5) human immunodeficiency virus type 1 (HIV-1), screened using the original Trofile assay.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP869707.RAPdhNVmmhjPnmmWMSenyOoUpkUfrCL_RChO-gnIlKwSM130_provenance.
- NP869707.RAPdhNVmmhjPnmmWMSenyOoUpkUfrCL_RChO-gnIlKwSM130_assertion evidence source_evidence_literature NP869707.RAPdhNVmmhjPnmmWMSenyOoUpkUfrCL_RChO-gnIlKwSM130_provenance.
- NP869707.RAPdhNVmmhjPnmmWMSenyOoUpkUfrCL_RChO-gnIlKwSM130_assertion SIO_000772 21288824 NP869707.RAPdhNVmmhjPnmmWMSenyOoUpkUfrCL_RChO-gnIlKwSM130_provenance.
- NP869707.RAPdhNVmmhjPnmmWMSenyOoUpkUfrCL_RChO-gnIlKwSM130_assertion wasDerivedFrom befree-2016 NP869707.RAPdhNVmmhjPnmmWMSenyOoUpkUfrCL_RChO-gnIlKwSM130_provenance.
- NP869707.RAPdhNVmmhjPnmmWMSenyOoUpkUfrCL_RChO-gnIlKwSM130_assertion wasGeneratedBy ECO_0000203 NP869707.RAPdhNVmmhjPnmmWMSenyOoUpkUfrCL_RChO-gnIlKwSM130_provenance.